Weight Gain and the Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation Carriers
Por:
Kim, SJ, Lubinski, J, Huzarski, T, Moller, P, Armel, S, Karlan, BY, Senter, L, Eisen, A, Foulkes, WD, Singer, CF, Tung, N, Bordeleau, L, Neuhausen, SL, Olopade, OI, Eng, C, Weitzel, JN, Fruscio, R, Narod, SA, Kotsopoulos, J, Cajal, T.R., Trister, Rachel
Publicada:
1 nov 2021
Resumen:
Background: Weight gain and other anthropometric measures on the risk of ovarian cancer for women with BRCA mutations are not known. We conducted a prospective analysis of weight change since age 18, height, body mass index (BMI) at age 18, and current BMI and the risk of developing ovarian cancer among BRCA1 and BRCA2 mutation carriers.
Methods: In this prospective cohort study, height, weight, and weight at age 18 were collected at study enrollment. Weight was updated biennially. Cox proportional hazards models were used to estimate the hazard ratio (HR) and 95% confidence intervals (CI) for ovarian cancer.
Results: This study followed 4,340 women prospectively. There were 121 incident cases of ovarian cancer. Weight gain of more than 20 kg since age 18 was associated with a 2-fold increased risk of ovarian cancer, compared with women who maintained a stable weight (HR, 2.00; 95% CI, 1.13-3.54; P = 0.02). Current BMI of 26.5 kg/m(2) or greater was associated with an increased risk of ovarian cancer in BRCA1 mutation carriers, compared with those with a BMI less than 20.8 kg/m(2) (Q4 vs. Q1 HR, 2.13; 95% CI, 1.04-4.36; P = 0.04). There were no significant associations between height or BMI at age 18 and risk of ovarian cancer.
Conclusions: Adult weight gain is a risk factor for ovarian cancer in women with a BRCA1 or BRCA2 mutation.
Impact: These findings emphasize the importance of maintaining a healthy body weight throughout adulthood in women at high risk for ovarian cancer.
Filiaciones:
Kim, SJ:
Womens Coll Hosp, Womens Coll Res Inst, 76 Grenville St,6th Floor, Toronto, ON M5S 1B2, Canada
Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada
Lubinski, J:
Pomeranian Med Univ, Int Hereditary Canc Ctr, Dept Genet & Pathol, Szczecin, Poland
Huzarski, T:
Pomeranian Med Univ, Int Hereditary Canc Ctr, Dept Genet & Pathol, Szczecin, Poland
Univ Zielona Gora, Dept Clin Genet & Pathol, Zielona Gora, Poland
Moller, P:
Oslo Univ Hosp, Norwegian Radium Hosp, Inst Canc Res, Dept Tumor Biol, Oslo, Norway
Armel, S:
Univ Hlth Network, Princess Margaret Hosp, Div Gynecol Oncol, Toronto, ON, Canada
Karlan, BY:
Univ Calif Los Angeles, David Geffen Sch Med, Dept Obstet & Gynecol, Los Angeles, CA USA
Senter, L:
Ohio State Univ, Comprehens Canc Ctr, Div Human Genet, Med Ctr, Columbus, OH USA
Eisen, A:
Toronto Sunnybrook Reg Canc Ctr, Toronto, ON, Canada
Foulkes, WD:
McGill Univ, Dept Oncol & Human Genet, Program Canc Genet, Montreal, PQ, Canada
Singer, CF:
Med Univ Vienna, Dept Obstet & Gynecol, Vienna, Austria
Med Univ Vienna, Comprehens Canc Ctr, Vienna, Austria
Tung, N:
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
Bordeleau, L:
Juravinski Canc Ctr, Dept Oncol, Hamilton, ON, Canada
Neuhausen, SL:
City Hope Natl Med Ctr, Div Biomarkers Early Detect & Prevent, Duarte, CA USA
Olopade, OI:
Univ Chicago, Dept Med & Human Genet, Chicago, IL 60637 USA
Eng, C:
Cleveland Clin, Ctr Personalized Genet Healthcare, Genom Med Inst, Cleveland, OH 44106 USA
Weitzel, JN:
Latin Amer Sch Oncol, Sierra Madre, CA USA
Fruscio, R:
Univ Milano Bicocca, Dept Med & Surg, Monza, Italy
Narod, SA:
Womens Coll Hosp, Womens Coll Res Inst, 76 Grenville St,6th Floor, Toronto, ON M5S 1B2, Canada
Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada
Kotsopoulos, J:
Womens Coll Hosp, Womens Coll Res Inst, 76 Grenville St,6th Floor, Toronto, ON M5S 1B2, Canada
Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada
Cajal, T.R.:
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Trister, Rachel:
University of Toronto Faculty of Medicine, Toronto, Canada
|